AOD-9604 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-09-29. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
=== DHIS2 === DHIS version 2 (from 2004) is a continuation of DHIS version 1 developed on open source Java technologies and available as an online web application. The first release, version 2.0, came in February 2008 after three years of development releases, and the most recent version is 43.0.1 (as of June 2026). DHIS2 is developed using open-source Java frameworks and tools, such as the Spring Framework, Hibernate, Struts2, Maven, and JUnit.
== Commercial production == Commercial onion powders are prepared using dehydration, freeze-drying, vacuum-shelf drying and flow drying. Some commercial onion powders are irradiated as a treatment against potential microbial contamination. It readily absorb water upon contact, so commercial varieties may be packaged in airtight containers with a liner atop the container. Onion powder with a moisture content of 4–5 percent is prone to caking when stored in warmer environments, with increased temperatures corresponding to a shorter time for the occurrence of caking. It is generally accepted that commercial onion powder is around ten times stronger in flavor compared to fresh onions.
The doctor who had ordered the tests was a diabetes expert who specialised in insulin and hypoglycaemic episodes, and she had believed the incident to be suspicious. No doctor or medical staff member had prescribed her this drug, and she had no condition that required it to be issued. The amount of insulin in Hall's blood was about 12 times the normal level, and it had been injected into her system. The insulin was manufactured and not produced naturally in the body. It had been injected into her abdomen, as indicated by the fact that a bulge was found under her skin there that was consistent with a large injection of fluid. Doctors believed it was done by someone with nursing or medical experience. The results of the tests led the hospital to contact the police. It was discovered after Hall's death that insulin had also been taken from the storage fridge, and Norris later admitted that he was the last person to have accessed this fridge before Hall had been injected with insulin. Two vials of insulin were found to have been taken from the fridge, which had to have been taken by someone during the night shift which Norris was working when Hall became unwell. Norris had on a previous occasion been caught stealing drugs from the hospital. Norris also admitted that he was the last person to see Hall at 4.30 am, half an hour before she fell into the hypoglycaemic coma. at around 5 am.
Sources: en.wikipedia.org
== Structure == Draculin is a single-chain protein composed of 708 amino acids, weighing about 83 kDa with a pI of 4.1-4.2. When reduced, the gel electrophoresis data indicates a slightly higher molecular mass suggesting intra-chain disulphide bonds. There are two different structural forms of Draculin. However, the two forms do not significantly differ from the other. Both structures are able to and do bind to coagulation factors IXa and Xa. The main difference is evident in inhibition activity. One structural form will inhibit factor IXa and the other Xa. The inhibitory activity of one factor is not affected by the presence of the other. FXa-Draculin complex is a two-step mechanism that, through experimental conditions, is irreversible.
tarnish A thin layer of corrosion that forms on the surface of copper, brass, aluminum, magnesium, and other soft metals or alloys as their outermost layer undergoes a chemical reaction with the surrounding air, often but not necessarily involving atmospheric oxygen. Tarnish usually appears as a dull grey, black, or sometimes iridescent film or coating on the metal. It is a self-limiting surface phenomenon, as the tarnished top layers of the metal protect underlying layers from reacting.
The U.S. Census Bureau reported 331,449,281 residents on April 1, 2020, making the United States the third-most-populous country in the world, after India and China. The Census Bureau's official 2025 population estimate was 341,784,857, an increase of 3.1% since the 2020 census. According to the Bureau's U.S. Population Clock, on July 1, 2024, the U.S. population had a net gain of one person every 16 seconds, or about 5400 people per day. In 2023, 51% of Americans age 15 and over were married, 6% were widowed, 10% were divorced, and 34% had never been married. In 2023, the total fertility rate for the U.S. stood at 1.6 children per woman, and, at 23%, it had the world's highest rate of children living in single-parent households in 2019. Most Americans live in the suburbs of major metropolitan areas. The United States has a diverse population; 37 ancestry groups have more than one million members. White Americans with ancestry from Europe, the Middle East, or North Africa form the largest racial and ethnic group at 57.8% of the United States population. Hispanic and Latino Americans form the second-largest group and are 18.7% of the United States population. African Americans constitute the country's third-largest ancestry group and are 12.1% of the total U.S. population. Asian Americans are the country's fourth-largest group, composing 5.9% of the United States population. The country's 3.7 million Native Americans account for about 1%, and some 574 native tribes are recognized by the federal government.
== External links == WHO Good Clinical Laboratory Practice (GCLP) (11 Oct 2010) MHRA guidance on the maintenance of regulatory compliance in laboratories that perform the analysis or evaluation of clinical trial samples (11 Oct 2010)
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.